fluticasone furoate/umeclidinium/vilanterol vs Ipratropium

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline

fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta

Marketed by GlaxoSmithKline

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Reliable signal

NCT02164513 · Phase 3 · completed

This was a large randomized, double-blind, active-controlled trial in 10,355 COPD patients at 971 sites in 37 countries; the primary endpoint, annual on-treatment moderate/severe exacerbation rate, is a hard clinical outcome, and triple therapy significantly reduced exacerbations versus both dual-therapy comparators (rate ratio 0.75 vs UMEC/VI and 0.85 vs FF/VI, both p<0.001).

Next expected readout: September 2027 · NCT07192016 (registry estimate)

Reported efficacy

Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI (Up to Week 52): Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001) (met)

Result source: NCT02164513

Ipratropium

Marketed by Boehringer Ingelheim

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfluticasone furoate/​umeclidinium/​vilanterolIpratropium
Moderate or severe exacerbations, annualised rate0.9 vs 1.1vs FF/VIwk 52 · n 4145NCT02164513
2 other results
  • 0.2 vs 0.3 100/62.5/25 µg · wk 24 · n 907 · Phase 3 · secondary NCT02345161
  • 0.2 vs 0.4 100/62.5/25 µg · wk 52 · n 210 · Phase 3 · secondary NCT02345161
—Not posted · NCT02177344
Trough FEV1, change0.1 vs -0.0vs BUD/FOR100/62.5/25 µg · wk 24 · n 836NCT02345161
14 other results
  • 0.1 vs -0.1 100/62.5/25 µg · wk 52 · n 183 · Phase 3 · primary NCT02345161
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.1 vs -0.0 wk 52 · n 3366 · Phase 3 · secondary NCT02164513
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 362 · Phase 4 · primary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 376 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs -0.0 100/62.5/25 mcg · wk 4 · n 385 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 358 · Phase 4 · secondary NCT03478683
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 0.29 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs 0.0 100/62.5/25 mcg · wk 0.29 · n 358 · Phase 4 · secondary NCT03478683
—Not posted · NCT02177344
SGRQ total, change-6.6 vs -4.3vs BUD/FOR100/62.5/25 µg · wk 24 · n 846NCT02345161
3 other results
  • -4.6 vs -1.9 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · primary NCT02345161
  • -5.5 vs -3.7 wk 52 · n 3318 · Phase 3 · secondary NCT02164513
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
—Not posted · NCT02177344
TDI focal score2.3 vs 1.7vs BUD/FOR100/62.5/25 µg · wk 24 · n 839NCT02345161
1 other result
  • 1.7 vs 1.4 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · secondary NCT02345161
—Not posted · NCT02177344

Moderate or severe exacerbations, annualised rate

fluticasone furoate/​umeclidinium/​vilanterol
0.9 vs 1.1vs FF/VIwk 52 · n 4145NCT02164513
2 other results
  • 0.2 vs 0.3 100/62.5/25 µg · wk 24 · n 907 · Phase 3 · secondary NCT02345161
  • 0.2 vs 0.4 100/62.5/25 µg · wk 52 · n 210 · Phase 3 · secondary NCT02345161
Ipratropium
—Not posted · NCT02177344

Trough FEV1, change

fluticasone furoate/​umeclidinium/​vilanterol
0.1 vs -0.0vs BUD/FOR100/62.5/25 µg · wk 24 · n 836NCT02345161
14 other results
  • 0.1 vs -0.1 100/62.5/25 µg · wk 52 · n 183 · Phase 3 · primary NCT02345161
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.1 vs -0.0 wk 52 · n 3366 · Phase 3 · secondary NCT02164513
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 362 · Phase 4 · primary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 376 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs -0.0 100/62.5/25 mcg · wk 4 · n 385 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 358 · Phase 4 · secondary NCT03478683
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 0.29 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs 0.0 100/62.5/25 mcg · wk 0.29 · n 358 · Phase 4 · secondary NCT03478683
Ipratropium
—Not posted · NCT02177344

SGRQ total, change

fluticasone furoate/​umeclidinium/​vilanterol
-6.6 vs -4.3vs BUD/FOR100/62.5/25 µg · wk 24 · n 846NCT02345161
3 other results
  • -4.6 vs -1.9 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · primary NCT02345161
  • -5.5 vs -3.7 wk 52 · n 3318 · Phase 3 · secondary NCT02164513
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
Ipratropium
—Not posted · NCT02177344

TDI focal score

fluticasone furoate/​umeclidinium/​vilanterol
2.3 vs 1.7vs BUD/FOR100/62.5/25 µg · wk 24 · n 839NCT02345161
1 other result
  • 1.7 vs 1.4 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · secondary NCT02345161
Ipratropium
—Not posted · NCT02177344
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Ipratropium: registry results are on file for Chronic Obstructive Pulmonary Disease, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. fluticasone furoate/umeclidinium/vilanterol: 4 of 4 rows · Ipratropium: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfluticasone furoate/​umeclidinium/​vilanterol
Dropout rate
10.5%FF/UMEC/VIa
NCT02164513 · Phase 3
show 9 more results
—100/62.5/25
NCT02164513 · Phase 3
4.9%100/62.5/25 µg
NCT02345161 · Phase 3
6.1%
NCT04923347 · Phase 4 · registry result, not featured evidence
9.5%
NCT05535972 · Phase 4 · registry result, not featured evidence
3%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
4.3%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
4.6%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
3.6%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
5.7%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
3.9%FF/UMEC/VIa
NCT02164513 · Phase 3
show 9 more results
—100/62.5/25
NCT02164513 · Phase 3
1.8%100/62.5/25 µg
NCT02345161 · Phase 3
—
NCT04923347 · Phase 4 · registry result, not featured evidence
1.3%
NCT05535972 · Phase 4 · registry result, not featured evidence
0.6%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
1.5%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
0.3%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
1.4%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
Serious AEs
—FF/UMEC/VIa
NCT02164513 · Phase 3
show 9 more results
21.6%100/62.5/25
NCT02164513 · Phase 3
6.7%100/62.5/25 µg
NCT02345161 · Phase 3
0.4%
NCT04923347 · Phase 4 · registry result, not featured evidence
4.1%
NCT05535972 · Phase 4 · registry result, not featured evidence
7.4%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
3.3%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
4.4%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
8%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
10.4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
100/62.5/25a
viral upper respiratory tract infection 12.5%
upper respiratory tract infection 7.2%
headache 5.6%
NCT02164513 · Phase 3
show 8 more results
100/62.5/25 µg
nasopharyngitis 7.9%
headache 4.8%
NCT02345161 · Phase 3
pyrexia 4.4%
headache 3.9%
NCT04923347 · Phase 4 · registry result, not featured evidence
dysphonia 0.4%
abdominal discomfort 0.2%
abdominal pain upper 0.2%
NCT05535972 · Phase 4 · registry result, not featured evidence
100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
dyspnoea 2.1%
NCT03467425 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
headache 4.5%
nasopharyngitis 4%
NCT03474081 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
headache 3.6%
nasopharyngitis 1.9%
NCT03478696 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
nasopharyngitis 5%
NCT03478683 · Phase 4 · registry result, not featured evidence
100/62.5/25
viral upper respiratory tract infection 10.6%
headache 6.1%
upper respiratory tract infection 3.4%
NCT02729051 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fluticasone furoate/umeclidinium/vilanterol

Moderate or Severe Exacerbation Rate Annualized 0.91 vs 1.07 FF/VI per year @ 52wk
event rate · per year
NCT02164513 · Phase 3
show 2 more results
0.22 vs 0.34 BUD/FOR per year @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
0.2 vs 0.36 BUD/FOR per year @ 52wk100/62.5/25 µg
NCT02345161 · Phase 3
FEV1 Trough 0.094 vs -0.003 FF/VI L @ 52wk
absolute change · L
NCT02164513 · Phase 3
show 14 more results
0.142 vs -0.029 BUD/FOR L @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
0.126 vs -0.053 BUD/FOR L @ 52wk100/62.5/25 µg
NCT02345161 · Phase 3
0.115 vs 0.02 Tiotropium L @ 12wk100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
0.115 vs -0.007 Tiotropium L @ 4wk100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
0.105 vs 0.018 Tiotropium L @ 12wk100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
0.015 vs -0.01 Budesonide/Formoterol Plus Tiotropium L @ 0.29wk100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
0.044 vs -0.019 Budesonide/Formoterol Plus Tiotropium L @ 4wk100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
0.024 vs -0.03 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
0.029 vs -0.022 Budesonide/Formoterol Plus Tiotropium L @ 12.14wk100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
0.008 vs 0.018 Budesonide/Formoterol Plus Tiotropium L @ 0.29wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
0.046 vs -0.015 Budesonide/Formoterol Plus Tiotropium L @ 4wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
0.04 vs -0.018 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
0.026 vs -0.012 Budesonide/Formoterol Plus Tiotropium L @ 12.14wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
0.113 vs 0.095 FF/VI + UMEC L @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
SGRQ Total -5.5 vs -3.7 FF/VI score @ 52wk
absolute change · score
NCT02164513 · Phase 3
show 3 more results
-6.6 vs -4.3 BUD/FOR score @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
-4.6 vs -1.9 BUD/FOR score @ 52wk100/62.5/25 µg
NCT02345161 · Phase 3
-5.841 vs -4.935 FF/VI + UMEC score @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
Time to First Moderate or Severe Exacerbation NA vs NA FF/VI months @ 52wk
time to event · months
Median time to onset
NCT02164513 · Phase 3
show 1 more result
NA vs 8.31 UMEC/VI months @ 52wk
Median time to onset
NCT02164513 · Phase 3
TDI Focal 2.29 vs 1.72 BUD/FOR score @ 24wk100/62.5/25 µg
absolute change · score
NCT02345161 · Phase 3
show 1 more result
1.74 vs 1.39 BUD/FOR score @ 52wk100/62.5/25 µg
NCT02345161 · Phase 3
EXACT-RS -1.45 vs -0.5 BUD/FOR score @ 4wk100/62.5/25 µg
absolute change · score
NCT02345161 · Phase 3
show 17 more results
-2 vs -0.77 BUD/FOR score @ 8wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.23 vs -1.05 BUD/FOR score @ 12wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.42 vs -1.09 BUD/FOR score @ 16wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.43 vs -1.02 BUD/FOR score @ 20wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.31 vs -0.96 BUD/FOR score @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
-1.24 vs -0.72 BUD/FOR score @ 4wk100/62.5/25 µg
NCT02345161 · Phase 3
-1.97 vs -0.9 BUD/FOR score @ 8wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.18 vs -1.21 BUD/FOR score @ 12wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.53 vs -1.52 BUD/FOR score @ 16wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.64 vs -1.53 BUD/FOR score @ 20wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.63 vs -1.52 BUD/FOR score @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.48 vs -1.16 BUD/FOR score @ 28wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.33 vs -0.9 BUD/FOR score @ 32wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.12 vs -0.62 BUD/FOR score @ 36wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.34 vs -1.11 BUD/FOR score @ 40wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.3 vs -0.81 BUD/FOR score @ 44wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.17 vs -0.64 BUD/FOR score @ 48wk100/62.5/25 µg
NCT02345161 · Phase 3
EXACT-RS -2.03 vs -0.61 BUD/FOR score @ 52wk100/62.5/25 µg
absolute change · score
EXACT-RS Scores, Week 49-52, n=179, 171
NCT02345161 · Phase 3
FEV1 Trough 0.0542 L @ 4wk
absolute change · L
No placebo or comparator arm
CFB to Day 28
NCT04923347 · Phase 4 · registry result, not featured evidence
FEV1 Trough 0.0317 L @ 12wk
absolute change · L
No placebo or comparator arm
CFB to Day 85
NCT04923347 · Phase 4 · registry result, not featured evidence
CAT Total -6.8 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
show 1 more result
-4.4 score @ 4wk
NCT05535972 · Phase 4 · registry result, not featured evidence
mMRC Dyspnea Scale -0.5 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
show 1 more result
-0.5 score @ 12wk
NCT05535972 · Phase 4 · registry result, not featured evidence
FEV1 0.132 L @ 12wk
absolute change · L
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence

+ 8 further endpoints in the CSV export.

Asthma

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline

fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule combination
Reliable signal

NCT02924688 · Phase 3 · completed

This was a large (N=2,436) randomized, triple-blind, active-controlled Phase III trial comparing four fixed-dose combinations of fluticasone furoate/umeclidinium/vilanterol against two fluticasone furoate/vilanterol dual therapy controls in patients with inadequately controlled asthma. The primary endpoint, change from baseline in trough FEV1 at Week 24, was met for every pre-specified triple-therapy versus dual-therapy comparison, with all four least-squares mean differences favoring triple therapy and p<0.001. The combination of randomization, blinding, an active comparator, a large sample, a hard clinical endpoint, and a statistically significant primary result constitutes strong evidence.

Next expected readout: January 2027 · NCT05757102 (registry estimate)

Reported efficacy

Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline (pre-dose at Day 1) and Week 24): Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). (met)

Result source: NCT02924688

Ipratropium

Marketed by Boehringer Ingelheim

Phase 3 in Asthmasmall molecule
Weak signal

NCT06074185 · Phase 2 · completed

The study was not randomized or blinded and compared patients treated before and after implementation of the bundle rather than using a concurrent controlled trial; the intervention also included dexamethasone and a checklist, so the effect cannot be attributed to ipratropium alone. Although hospital admission is a clinical endpoint, the primary comparison was based on a small and internally inconsistent set of reported participants, with no reported significance analysis, so the result is unclear.

No aligned efficacy figure on record for this race.

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointfluticasone furoate/​umeclidinium/​vilanterolIpratropium
Severe exacerbations, annualised rate—Trial running · NCT04651777—Not reported
Trough FEV1, change0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387
—Not reported
ACQ-5, change—Trial running · NCT04651777—Not reported
OCS dose reduction—Trial running · NCT04651777—Not reported

Severe exacerbations, annualised rate

fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
Ipratropium
—Not reported

Trough FEV1, change

fluticasone furoate/​umeclidinium/​vilanterol
0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387
Ipratropium
—Not reported

ACQ-5, change

fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
Ipratropium
—Not reported

OCS dose reduction

fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
Ipratropium
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. fluticasone furoate/umeclidinium/vilanterol: 4 of 4 rows · Ipratropium: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfluticasone furoate/​umeclidinium/​vilanterolIpratropium
Dropout rate
7.7%100/31.25/25 mcga
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.9%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
3.4%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
11.1%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
7.3%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
—b
NCT06074185 · Phase 2 · combination
show 4 more results
0%
NCT04617015 · Phase 1 · registry result, not featured evidence
0%Arg/Arg Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
5.6%Gly/Gly Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
0%
NCT00583778 · Phase na · registry result, not featured evidence · combination
Discontinued due to AEs
0.7%100/31.25/25 mcga
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
0.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
1.8%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
—b
NCT06074185 · Phase 2 · combination
show 4 more results
—
NCT04617015 · Phase 1 · registry result, not featured evidence
—Arg/Arg Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
—Gly/Gly Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
—
NCT00583778 · Phase na · registry result, not featured evidence · combination
Serious AEs
4.4%100/31.25/25 mcga
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.1%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
1.1%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
3.3%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
3.6%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%b
NCT06074185 · Phase 2 · combination
show 4 more results
0%
NCT04617015 · Phase 1 · registry result, not featured evidence
0%Arg/Arg Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
0%Gly/Gly Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
0%
NCT00583778 · Phase na · registry result, not featured evidence · combination
Most frequent reported AEs
100/31.25/25 mcga
nasopharyngitis 13.8%
headache 7.7%
upper respiratory tract infection 5.9%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
200/31.25/25 mcg
nasopharyngitis 12.6%
headache 6.7%
bronchitis 4%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 14.8%
headache 8.9%
bronchitis 3.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
200/62.5/25 mcg
nasopharyngitis 12.5%
bronchitis 5.4%
headache 4.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
FF 200 ug, UMEC 62.5 ug, VI 25 ug
covid-19 5.7%
nasopharyngitis 4.5%
upper respiratory tract infection 4.5%
NCT04937387 · Phase 3 · Asthma · phase 3
FF 100 ug, UMEC 62.5 ug, VI 25 ug
upper respiratory tract infection 7.8%
covid-19 3.3%
nasopharyngitis 3.3%
NCT04937387 · Phase 3 · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 27.7%
pharyngitis 10.6%
bronchitis 8.5%
NCT03184987 · Phase 3 · combination
100/62.5/25 mcg to 200/62.5/25 mcg
bronchitis 22.2%
dysgeusia 22.2%
nasopharyngitis 22.2%
NCT03184987 · Phase 3 · combination
200/62.5/25 mcg
nasopharyngitis 32.7%
dysgeusia 10.9%
eczema 9.1%
NCT03184987 · Phase 3 · combination
b
upper respiratory infection 13.3%
dyspnea 6.7%
right foot fracture 6.7%
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
dyspnea 11.8%
cough 5.9%
pneumonia 5.9%
NCT00521222 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fluticasone furoate/umeclidinium/vilanterol

FEV1 Trough 0.116 vs 0.121 Fluticasone Furoate [FF] / Vilanterol [VI] L @ 12wkFF 200 ug, UMEC 62.5 ug, VI 25 ug
absolute change · L
NCT04937387 · Phase 3 · Asthma · phase 3
show 5 more results
0.136 vs 0.078 Fluticasone Furoate [FF] / Vilanterol [VI] L @ 12wkFF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0.12 vs 0.024 FF/VI L @ 24wk100/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.157 vs 0.024 FF/VI L @ 24wk200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.134 vs 0.024 FF/VI L @ 24wk100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.168 vs 0.024 FF/VI L @ 24wk200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
FEV1 Change 3 h 0.22 vs 0.132 FF/VI L @ 24wk100/31.25/25 mcg
absolute change · L
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 3 more results
0.256 vs 0.132 FF/VI L @ 24wk200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.243 vs 0.132 FF/VI L @ 24wk100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.286 vs 0.132 FF/VI L @ 24wk200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
ACQ-7 -0.814 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 200 ug, UMEC 62.5 ug, VI 25 ug
absolute change · score
NCT04937387 · Phase 3 · Asthma · phase 3
show 1 more result
-0.968 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3

Ipratropium

PROMIS Asthma Impact Scale 22.5 score @ 1wk
absolute value · score
No placebo or comparator arm
NCT06074185 · Phase 2 · combination
FEV1 10.8% (n=39)
percent change · % of baseline
No placebo or comparator arm
NCT04617015 · Phase 1 · registry result, not featured evidence
show 1 more result
8.9% (n=32)
NCT04617015 · Phase 1 · registry result, not featured evidence
Morning PEF Change L/Min -15.7 vs -5.6 Fluticasone HFA L/min @ 16wk
absolute change · L/min
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
8.4 vs -5.6 Fluticasone HFA L/min @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
FEV1 -0.03 vs -0.12 Fluticasone HFA L @ 16wk
absolute change · L
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-0.08 vs -0.12 Fluticasone HFA L @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
Post-BD FEV1 Change 0.02 vs -0.11 Fluticasone HFA L @ 16wk
absolute change · L
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-0.07 vs -0.11 Fluticasone HFA L @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
FEV1% Predicted -1% (n=15) vs -3.8% (n=13) Fluticasone HFA @ 16wk
absolute change · percentage points
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-2.5% (n=17) vs -3.8% (n=13) Fluticasone HFA @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
Asthma Symptom 0.3 vs 0.4 Fluticasone HFA score @ 16wk
absolute change · score
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-1.2 vs 0.4 Fluticasone HFA score @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
FEV1 47.5% (n=141) vs 52.5% (n=141) Levalbuterol @ 0wk
responder rate · % of participants
NCT00583778 · Phase na · registry result, not featured evidence · combination · converted to % from 67 Participants as posted
FEV1 Percent Predicted 47% (n=67) vs 45% (n=74) Levalbuterol @ 0wk
absolute change · percentage points
NCT00583778 · Phase na · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/umeclidinium/vilanterol's landscape · Ipratropium's landscape